R&D | Cutting-edge science and innovative research

News

MHRA grants Innovation Passports to three novel drugs

The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.

R&D

Europe’s growing vector-borne disease threat: Are we keeping...

In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.

News

argenx agrees Unnatural takeover deal worth up to $1.15bn

argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.

News

Novartis' pelacarsen fail raises questions for other drugs

The data from Novartis' disappointing cardiovascular outcomes trial with Lp(a)-targeting pelacarsen have been revealed, leaving cardiologists puzzled.

News

Inflammation-focused Rezera sets terms for IPO

Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.

News

Novartis succeeds where Roche failed with PI3K breast cancer...

Novartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation, after other pharma giants including Roche failed and abandoned

News

AC Immune trials Alzheimer’s vaccine

Switzerland's AC Immune biopharma has begun mid-stage trials of a vaccine against Alzheimer’s disease and Abeta-related cognitive decline in Down Syndrome patients.

Views & Analysis

Artificial intelligence in drug discovery and diagnosis

Machine learning is widely predicted to make drug discovery and patient diagnosis quicker, cheaper and more effective in the future, and signs of this can already be seen.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

MHRA grants Innovation Passports to three novel drugs

The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.

News

argenx agrees Unnatural takeover deal worth up to $1.15bn

argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Europe’s growing vector-borne disease threat: Are we keeping...

In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.

R&D

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

R&D

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

Event

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Partner Content

Europe's Largest Gathering for ADC Innovation

Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community

Event

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Partner Content

Europe's Largest Gathering for ADC Innovation

Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community

Event

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights

MHRA grants Innovation Passports to three novel drugs

Europe’s growing vector-borne disease threat: Are we keeping...

argenx agrees Unnatural takeover deal worth up to $1.15bn

Novartis' pelacarsen fail raises questions for other drugs

Inflammation-focused Rezera sets terms for IPO

Novartis succeeds where Roche failed with PI3K breast cancer...

AC Immune trials Alzheimer’s vaccine

Artificial intelligence in drug discovery and diagnosis

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

MHRA grants Innovation Passports to three novel drugs

argenx agrees Unnatural takeover deal worth up to $1.15bn

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

The Evolution Summit Announces September 2026 Program for Cl...

Europe’s growing vector-borne disease threat: Are we keeping...

Kidney care raises its ambitions at ASN Kidney Week 2026

Why the best CROs challenge the trial plan and keep challeng...

Cancer misinformation is a trust problem, not just an inform...

The GLP-1 Reckoning

Designing obesity trials around real lives: How patient cent...

The future of cardiometabolic trials: From obesity to outcom...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

Bioconvergence & future human health, with Shai Melcer

Understanding Operation Trialblazer, with Dr Harpreet Singh

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Boosting biotech in Basel – with Valentina Francia

Beyond recruitment: Creating patient engagement that lasts

Taking the microbiome seriously, with Sam Possemiers

From Alzheimer’s disease research to the real-world setting:...

A data-driven guide to small molecule drug discovery and dev...

A New Framework to Engineer Breakthrough Value for Medicines

Rational Based Drug Design Summit Europe

Europe's Largest Gathering for ADC Innovation

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

Rational Based Drug Design Summit Europe

Europe's Largest Gathering for ADC Innovation

3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...

FDA orders blindness risk warning to GLP-1 agonist labels

Discover a new era of healthcare panel engagement: Grounded ...

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks